Breast Cancer Trials 41st Annual Scientific Meeting

Pinterest LinkedIn Tumblr +

De-escalation was a major theme at the Breast Cancer Trials 41st Annual Scientific Meeting (ASM) in Adelaide.

The conference attracted more than 240 delegates to hear about the latest news in breast cancer clinical trials research, from leading Australian and International speakers.

With more women surviving their breast cancer diagnosis than ever before, a number of presentations discussed how clinicians may improve the quality of life of patients through less treatment.

In their opening sessions, the three international guest speakers shared their experiences of de-escalation:

  • Professor Julia White spoke on de-escalation strategies in breast conserving therapies;
  • Dr Stuart McIntosh spoke on UK studies that are currently open, such as the LORIS, SMALL, PRIMETIME, OPTIMA, NOSTRA, POSNOC and ATNEC clinical trials; and
  • Associate Professor Aleix Pratt discussed HER2 positive breast cancer molecular biomarkers and how they may guide de-escalation treatment.

Professor Julia White speaking at the Breast Cancer Trials ASM

For the first time, the ASM featured a Concept Development Workshop where Breast Cancer Trials (BCT) members were invited to submit new research ideas and a number were selected for presentation. This will become a yearly session during the ASM and several research concepts presented at the workshop this year will now go on for further development.

Each year, BCT has the pleasure of presenting a number of awards to members and researchers, in recognition of their commitment to BCT and contributions to breast cancer clinical trials research.

The Gold Medal was presented to Professor Martin Tattersall as a founding member of BCT and for his 40-year contribution to research endeavours.

Professor Sherene Loi received The Robert Sutherland Award for Translational Research, in recognition of her achievements and contributions to improved patient outcomes. Professor Loi currently has two immunotherapy clinical trials open through BCT, called DIAmOND and CHARIOT.

The John Collins Medal and Travel Grant is awarded to potential academic breast surgeons to become involved in clinical trials research and was presented to Dr Holly Keane and Dr Anannya Chakrabarti.

This year was the second time BCT hosted a Q&A event for the public to attend during the conference, which features a panel of breast cancer experts and clinical trial participants to discuss breast cancer topics. The event was moderated by Mamamia founder Mia Freedman and was broadcast live on Facebook. The entire event can be viewed on the BCT YouTube page.

Following the ASM, BCT has produced a number of resources involving leading breast cancer researchers. The following interviews were recorded at the ASM:

The Breast Cancer Trials Podcast also features a number of interviews recorded during the ASM with speakers from the conference. To listen or subscribe to the Podcast, click here.

BCT’s 42nd Annual Scientific Meeting will be held from 22-24 July 2020 in Auckland, New Zealand.

Source: Breast Cancer Trials


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.